Global Diabetes Drugs Market Report and Forecast 2023-2031
Global Diabetes Drugs Market Outlook
The global diabetes drugs market value was USD 70.7 billion in 2022, driven by the increasing prevalence of diabetes across the globe. The market is anticipated to grow at a CAGR of 5.3% during the forecast period of 2023-2031 to achieve a value of USD 112.6 billion by 2031.
Diabetes Drugs Introduction
Diabetes drugs are medications used to lower blood sugar levels in individuals with diabetes. These drugs help manage diabetes by either increasing insulin production or sensitivity, inhibiting the absorption of carbohydrates in the intestines, or slowing down the release of glucose from the liver.
The diabetes drugs market is primarily driven by the increasing prevalence of diabetes globally. The rise in the number of diabetic patients has led to a surge in the demand for diabetes drugs. Additionally, the growing awareness about diabetes management and the availability of advanced diabetes drugs are also fueling market growth.
Moreover, the introduction of technologically advanced products such as insulin pumps and continuous glucose monitoring systems has transformed the way diabetes is managed, further boosting the demand for diabetes drugs. On the other hand, patent expiration and the resultant entry of generic drugs into the market pose a significant challenge to market growth.
Overall, the diabetes drugs market is expected to witness continued growth in the coming years, driven by increasing patient awareness, rising healthcare expenditure, and ongoing R&D efforts to develop innovative diabetes drugs.
Diabetes Drugs Market Scenario
The global diabetes drugs market is a rapidly growing segment within the overall pharmaceutical industry. Diabetes is a chronic disease that affects millions of people worldwide, and the demand for effective treatments has been increasing steadily over the years. Diabetes drugs are used to regulate blood sugar levels in patients with type 1 and type 2 diabetes.
The market for diabetes drugs is driven by several factors, including an increase in the prevalence of diabetes worldwide, the rise in healthcare expenditure, and the availability of new drugs with improved efficacy and safety profiles. The market is also influenced by the increasing adoption of innovative drug delivery systems and the growing demand for personalized diabetes management solutions.
The diabetes drugs market is highly competitive, with several major players competing for market share. Companies in this space are focusing on developing novel drugs and improving existing treatments to meet the evolving needs of patients.
Overall, the diabetes drugs market is expected to continue to grow at a significant rate in the coming years, driven by the increasing demand for effective diabetes treatments and the development of new and innovative drugs.
Diabetes Drugs Market Segmentations
Market Breakup by Drugs
- Oral Anti-diabetic Drugs
- Alpha-glucosidase Inhibitor
- Biguanides
- Bile Acid Sequestrants
- Dopamine-2 Agonists
- DPP-4 Inhibitors
- Meglitinides
- SLGT2 Inhibitors
- Sulfonylureas
- TZDs
- Oral Combination Therapy
- Insulin
- Insulin Glargine
- Insulin Aspart
- Human Insulin
- Biosimilar Insulin
- Type I
- Type II
- Online
- Hospital
- Retail Pharmacies
- Hospital
- Clinics
- Personal Use
- Other
- North America
- United States of America
- Canada
- Europe
- United Kingdom
- Germany
- France
- Italy
- Others
- Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
- Latin America
- Brazil
- Argentina
- Mexico
- Others
- Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others
Key Trends in the Diabetes Drugs Market
Some key trends in the diabetes drugs market are:
- Increasing prevalence of diabetes: The increasing prevalence of diabetes worldwide is driving the growth of the diabetes drugs market. According to the International Diabetes Federation, approximately 463 million adults were living with diabetes in 2019, and this number is expected to rise to 700 million by 2045.
- Rising adoption of insulin analogs: The adoption of insulin analogs is increasing as they offer several advantages over traditional insulin such as more predictable action, fewer side effects, and improved glycemic control. The demand for insulin analogs is expected to grow in the coming years
- Development of combination therapies: The development of combination therapies that offer better glycemic control with fewer side effects is another key trend in the diabetes drugs market. Several pharmaceutical companies are focusing on developing combination therapies to improve treatment outcomes for patients.
- Increasing focus on patient-centric care: There is an increasing focus on patient-centric care in the diabetes drugs market, with a greater emphasis on improving patient outcomes and quality of life. This has led to the development of new drugs and therapies that offer better glycemic control with fewer side effects.
- Growing investment in R&D: The increasing investment in research and development (R&D) activities by pharmaceutical companies is driving innovation in the diabetes drugs market. This is leading to the development of new drugs and therapies that offer improved treatment outcomes for patients.
Diabetes Drugs Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the xx market are as follows:
- AstraZeneca Plc.
- Sanofi-aventis Groupe
- Merck & Co., Inc.
- Eli Lilly and Company.
- Home Diagnostics Inc.
- Takeda Pharmaceutical Company Limited.
- Novartis AG
- Boehringer Ingelheim International GmbH
- Novo Nordisk A/S
- Ypsomed AG
- Eli Lilly and Company
- Ascensia Diabetes Care Holdings AG
- Dexcom, Inc.
- Sanofi-Deutschland GmbH
- Roche Products Limited
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Diabetes Overview
- 3.1 Guidelines and Stages
- 3.2 Pathophysiology
- 3.3 Screening and Diagnosis
- 3.4 Treatment Pathway
- 4 Patient Profile
- 4.1 Patient Profile Overview
- 4.2 Patient Psychology and Emotional Impact Factors
- 4.3 Risk Assessment and Treatment Success Rate
- 5 Diabetes Epidemiology Analysis
- 5.1 Epidemiology Overview (2016-2031)
- 5.2 North America Diabetes Epidemiology (2016-2031)
- 5.3 Europe Diabetes Epidemiology (2016-2031)
- 5.4 Asia-Pacific Diabetes Epidemiology (2016-2031)
- 5.5 Latin America Diabetes Epidemiology (2016-2031)
- 5.6 Middle East & Africa Diabetes Epidemiology (2016-2031)
- 6 Global Diabetes Drugs Market Overview
- 6.1 Global Diabetes Drugs Market Historical Value (2016-2022)
- 6.2 Global Diabetes Drugs Market Forecast Value (2023-2031)
- 7 Global Diabetes Drugs Market Landscape
- 7.1 Diabetes Drugs: Developers Landscape
- 7.1.1 Analysis by Year of Establishment
- 7.1.2 Analysis by Company Size
- 7.1.3 Analysis by Region
- 7.2 Diabetes Drugs: Product Landscape
- 7.2.1 Analysis by Drug
- 7.2.2 Analysis by Diabetes Type
- 7.2.3 Analysis by Distribution Channel
- 7.2.4 Analysis by End User
- 8 Diabetes Treatment Challenges and Unmet Needs
- 8.1 Treatment Pathway Challenges
- 8.2 Compliance and Drop-Out Analysis
- 8.3 Awareness and Prevention Gaps
- 9 Cost of Treatment
- 10 Global Diabetes Drugs Market Dynamics
- 10.1 Market Drivers and Constraints
- 10.2 SWOT Analysis
- 10.3 Porter’s Five Forces Model
- 10.4 Key Demand Indicators
- 10.5 Key Price Indicators
- 10.6 Industry Events, Initiatives, and Trends
- 10.7 Value Chain Analysis
- 11 Global Diabetes Drugs Market Segmentation
- 11.1 Global Diabetes Drugs Market by Drugs
- 11.1.1 Market Overview
- 11.1.2 Oral Anti-diabetic Drugs
- 11.1.2.1 Alpha-glucosidase Inhibitor
- 11.1.2.2 Biguanides
- 11.1.2.3 Bile Acid Sequestrants
- 11.1.2.4 Dopamine-2 Agonists
- 11.1.2.5 DPP-4 Inhibitors
- 11.1.2.6 Meglitinides
- 11.1.2.7 SLGT2 Inhibitors
- 11.1.2.8 Sulfonylureas
- 11.1.2.9 TZDs
- 11.1.2.10 Oral Combination Therapy
- 11.1.3 Insulin
- 11.1.3.1 Insulin Glargine
- 11.1.3.2 Insulin Aspart
- 11.1.3.3 Human Insulin
- 11.1.3.4 Biosimilar Insulin
- 11.2 Global Diabetes Drugs Market by Diabetes Type
- 11.2.1 Market Overview
- 11.2.2 Type I
- 11.2.3 Type II
- 11.3 Global Diabetes Drugs Market by Distribution Channel
- 11.3.1 Market Overview
- 11.3.2 Online Retailers
- 11.3.3 Hospital Pharmacies
- 11.3.4 Retail Pharmacies
- 11.4 Global Diabetes Drugs Market by End User
- 11.4.1 Market Overview
- 11.4.2 Hospital
- 11.4.3 Clinics
- 11.4.4 Personal Use
- 11.4.5 Other
- 11.5 Global Diabetes Drugs Market by Region
- 11.5.1 Market Overview
- 11.5.2 North America
- 11.5.3 Europe
- 11.5.4 Asia Pacific
- 11.5.5 Latin America
- 11.5.6 Middle East and Africa
- 12 North America Diabetes Drugs Market
- 12.1 Market Share by Country
- 12.2 United States of America
- 12.3 Canada
- 13 Europe Diabetes Drugs Market
- 13.1 Market Share by Country
- 13.2 United Kingdom
- 13.3 Germany
- 13.4 France
- 13.5 Italy
- 13.6 Others
- 14 Asia Pacific Diabetes Drugs Market
- 14.1 Market Share by Country
- 14.2 China
- 14.3 Japan
- 14.4 India
- 14.5 ASEAN
- 14.6 Australia
- 14.7 Others
- 15 Latin America Diabetes Drugs Market
- 15.1 Market Share by Country
- 15.2 Brazil
- 15.3 Argentina
- 15.4 Mexico
- 15.5 Others
- 16 Middle East and Africa Diabetes Drugs Market
- 16.1 Market Share by Country
- 16.2 Saudi Arabia
- 16.3 United Arab Emirates
- 16.4 Nigeria
- 16.5 South Africa
- 16.6 Others
- 17 Regulatory Framework
- 17.1 Regulatory Overview
- 17.1.1 US FDA
- 17.1.2 EU EMA
- 17.1.3 INDIA CDSCO
- 17.1.4 JAPAN PMDA
- 17.1.5 Others
- 18 Patent Analysis
- 18.1 Analysis by Type of Patent
- 18.2 Analysis by Publication year
- 18.3 Analysis by Issuing Authority
- 18.4 Analysis by Patent Age
- 18.5 Analysis by CPC Analysis
- 18.6 Analysis by Patent Valuation
- 18.7 Analysis by Key Players
- 19 Grants Analysis
- 19.1 Analysis by year
- 19.2 Analysis by Amount Awarded
- 19.3 Analysis by Issuing Authority
- 19.4 Analysis by Grant Application
- 19.5 Analysis by Funding Institute
- 19.6 Analysis by NIH Departments
- 19.7 Analysis by Recipient Organization
- 20 Clinical Trials Analysis
- 20.1 Analysis by Trial Registration Year
- 20.2 Analysis by Trial Status
- 20.3 Analysis by Trial Phase
- 20.4 Analysis by Therapeutic Area
- 20.5 Analysis by Geography
- 21 Funding and Investment Analysis
- 21.1 Analysis by Funding Instances
- 21.2 Analysis by Type of Funding
- 21.3 Analysis by Funding Amount
- 21.4 Analysis by Leading Players
- 21.5 Analysis by Leading Investors
- 21.6 Analysis by Geography
- 22 Partnership and Collaborations Analysis
- 22.1 Analysis by Partnership Instances
- 22.2 Analysis by Type of Partnership
- 22.3 Analysis by Leading Players
- 22.4 Analysis by Geography
- 23 Supplier Landscape
- 23.1 Eli Lilly and Company
- 23.1.1 Financial Analysis
- 23.1.2 Product Portfolio
- 23.1.3 Demographic Reach and Achievements
- 23.1.4 Mergers and Acquisitions
- 23.1.5 Certifications
- 23.2 AstraZeneca Plc.
- 23.2.1 Novo Nordisk A/S
- 23.2.2 Product Portfolio
- 23.2.3 Demographic Reach and Achievements
- 23.2.4 Mergers and Acquisitions
- 23.2.5 Certifications
- 23.3 Sanofi-aventis Groupe
- 23.3.1 Financial Analysis
- 23.3.2 Product Portfolio
- 23.3.3 Demographic Reach and Achievements
- 23.3.4 Mergers and Acquisitions
- 23.3.5 Certifications
- 23.4 Merck & Co., Inc.
- 23.4.1 Financial Analysis
- 23.4.2 Product Portfolio
- 23.4.3 Demographic Reach and Achievements
- 23.4.4 Mergers and Acquisitions
- 23.4.5 Certifications
- 23.5 Home Diagnostics Inc.
- 23.5.1 Financial Analysis
- 23.5.2 Product Portfolio
- 23.5.3 Demographic Reach and Achievements
- 23.5.4 Mergers and Acquisitions
- 23.5.5 Certifications
- 23.6 Takeda Pharmaceutical Company Limited.
- 23.6.1 Financial Analysis
- 23.6.2 Product Portfolio
- 23.6.3 Demographic Reach and Achievements
- 23.6.4 Mergers and Acquisitions
- 23.6.5 Certifications
- 23.7 Novartis AG
- 23.7.1 Financial Analysis
- 23.7.2 Product Portfolio
- 23.7.3 Demographic Reach and Achievements
- 23.7.4 Mergers and Acquisitions
- 23.7.5 Certifications
- 23.8 Boehringer Ingelheim International GmbH
- 23.8.1 Financial Analysis
- 23.8.2 Product Portfolio
- 23.8.3 Demographic Reach and Achievements
- 23.8.4 Mergers and Acquisitions
- 23.8.5 Certifications
- 23.9 Novo Nordisk A/S
- 23.9.1 Financial Analysis
- 23.9.2 Product Portfolio
- 23.9.3 Demographic Reach and Achievements
- 23.9.4 Mergers and Acquisitions
- 23.9.5 Certifications
- 23.10 Ypsomed AG
- 23.10.1 Financial Analysis
- 23.10.2 Product Portfolio
- 23.10.3 Demographic Reach and Achievements
- 23.10.4 Mergers and Acquisitions
- 23.10.5 Certifications
- 23.11 Ascensia Diabetes Care Holdings AG
- 23.11.1 Financial Analysis
- 23.11.2 Product Portfolio
- 23.11.3 Demographic Reach and Achievements
- 23.11.4 Mergers and Acquisitions
- 23.11.5 Certifications
- 23.12 Dexcom, Inc.
- 23.12.1 Financial Analysis
- 23.12.2 Product Portfolio
- 23.12.3 Demographic Reach and Achievements
- 23.12.4 Mergers and Acquisitions
- 23.12.5 Certifications
- 23.13 Sanofi-Deutschland GmbH
- 23.13.1 Financial Analysis
- 23.13.2 Product Portfolio
- 23.13.3 Demographic Reach and Achievements
- 23.13.4 Mergers and Acquisitions
- 23.13.5 Certifications
- 23.14 Roche Products Limited
- 23.14.1 Financial Analysis
- 23.14.2 Product Portfolio
- 23.14.3 Demographic Reach and Achievements
- 23.14.4 Mergers and Acquisitions
- 23.14.5 Certifications
- 24 Diabetes Drugs - Distribution Model (Additional Insight)
- 24.1 Overview
- 24.2 Potential Distributors
- 24.3 Key Parameters for Distribution Partner Assessment
- 25 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 26 Company Competitiveness Analysis (Additional Insight)
- 26.1 Very Small Companies
- 26.2 Small Companies
- 26.3 Mid-Sized Companies
- 26.4 Large Companies
- 26.5 Very Large Companies
- 27 Payment Methods (Additional Insight)
- 27.1 Government Funded
- 27.2 Private Insurance
- 27.3 Out-of-Pocket
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook